AffiliationCRC Department of Medical Oncology, Christie Hospital, Manchester, UK.
MetadataShow full item record
AbstractBlood progenitor cells (BPC) are increasingly used in a variety of clinical settings. These include autologous and allogeneic transplantation after myeloablative therapy, and gene therapy. The optimal blood products for each of these applications have not been defined. The use of different cytotoxic drugs and cytokines, alone and in combination, results in the mobilisation of different total numbers and relative proportions of primitive and committed BPC. Some cytotoxics and cytokines not only are poor at mobilising BPC, but also are myelotoxic. Here we review the biology of BPC mobilisation and its implications for their clinical use.
CitationBiology of blood progenitor cells used in transplantation. 1995, 61 (1):1-15 Int. J. Hematol.
JournalInternational Journal of Hematology
- The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells .
- Authors: Haas R, Murea S
- Issue date: 1995 Dec
- Loss of marrow reserve from dose-intensified chemotherapy results in impaired hematopoietic reconstitution after autologous transplantation: CD34(+), CD34(+)38(-), and week-6 CAFC assays predict poor engraftment.
- Authors: Robinson SN, Freedman AS, Neuberg DS, Nadler LM, Mauch PM
- Issue date: 2000 Dec
- The whys and hows of hematopoietic progenitor and stem cell mobilization.
- Authors: Kessinger A, Sharp JG
- Issue date: 2003 Mar
- Ex vivo expansion of hematopoietic cells and their clinical use.
- Authors: Aglietta M, Bertolini F, Carlo-Stella C, De Vincentiis A, Lanata L, Lemoli RM, Olivieri A, Siena S, Zanon P, Tura S
- Issue date: 1998 Sep
- Blast counts in blood progenitor cell (BPC) correlate with CD34+ cells and CFU-GM and are useful predictor of haemopoietic recovery after autologous BPC transplantation collections.
- Authors: Mijovic A, Fishlock K, Pagliuca A, Mufti GJ
- Issue date: 1998 May